AZN Jan 2025 82.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

3.2500

+0.0500

(+1.56%)

As of 09:59AM EDT. Market open.

Loading interactive chart…

Zacks
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.
Zacks
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
Simply Wall St.
Investors in AstraZeneca (LON:AZN) have seen strong returns of 115% over the past five years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...